Prime Medicine Inc (PRME) — Institutional Holders Breakdown (Q2 2026)

PRME ranks #3139 out of 37696 tracked stocks by institutional interest — one of the most closely watched names in our coverage.

PRME is a disclosed holding of Cathie Wood (ARK Investment Management), one of the tracked superinvestors on AlphaSMO — it makes up 0.2% of that fund's own 13F portfolio.

190 institutions disclose a position in PRME, but none treat it as a major bet — even Alessandra Capital Management, LLC, its most concentrated holder, allocates just 1.7% of its own portfolio to it.

Wealth Enhancement Advisory Services, LLC has trimmed its PRME position for two straight quarters, cutting it by $84.0K while still holding $41.1K.

PRME is down 3.9% today, but institutions show net buying of $51.8M this quarter — a divergence between today's price move and the underlying institutional flow.

PRME reported a net loss of $187.9M over the trailing twelve months.

• Not yet profitable — net loss of $187.9M over the trailing twelve months
• Revenue grew 55.3% year over year
• Net income improved year over year, from -$199.3M to -$187.9M
• Operating cash flow was negative, using $162.6M in cash
• Current ratio of 4.84x — enough short-term assets to cover short-term liabilities
• Liabilities run 1.84x equity — within a conventional range